SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
47,250
-200 (-0.42%)
Last updated: Jul 25, 2025
-12.13%
Market Cap3.72T
Revenue (ttm)399.83B
Net Income (ttm)-47.63B
Shares Out78.37M
EPS (ttm)-613.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume130,724
Average Volume99,638
Open47,800
Previous Close47,600
Day's Range47,350 - 48,900
52-Week Range35,800 - 61,500
Beta1.22
RSI50.42
Earnings DateAug 12, 2025

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 984
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.